Clinical experience with pamidronate in the treatment of Paget's disease of bone (Q33564104)

28 July 2017

title

Clinical experience with pamidronate in the treatment of Paget's disease of bone (English)

1 reference

28 July 2017

main subject

Paget's disease of bone

1 reference

Gallacher SJ

1

1 reference

28 July 2017

Boyce BF

2

1 reference

28 July 2017

Patel U

3

1 reference

28 July 2017

Jenkins A

4

1 reference

28 July 2017

Ralston SH

5

1 reference

28 July 2017

Boyle IT

6

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 December 1991

1 reference

Annals of the Rheumatic Diseases

28 July 2017

published in

1 reference

28 July 2017

volume

50

1 reference

28 July 2017

issue

12

1 reference

28 July 2017

page(s)

930-933

1 reference

The hypercalcemia of malignancy: pathogenesis and management

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1004585

Immobilisation hypercalcaemia in adults and treatment with clodronate

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1004585

Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1004585

Response of Paget's disease to porcine and salmon calcitonins: effects of long-term treatment.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1004585

Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1004585

Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1004585

Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1004585

21 June 2018

Treating Paget's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1004585

Absorption of oral diphosphonate in normal subjects

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1004585

Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1004585

Intravenous clodronate in the treatment and retreatment of Paget's disease of bone.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1004585

Development and significance of antibodies to salmon calcitonin in patients with Paget's disease on long-term treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1004585

Treatment of Paget's disease of bone with mithramycin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1004585

Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1004585

Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1004585

Side-effects of pamidronate

21 June 2018

1 reference

12 December 2020

A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone

1 reference

12 December 2020

Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP

1 reference

12 December 2020

Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease

1 reference

12 December 2020

Treatment of Paget's disease of bone

1 reference

12 December 2020

Long term effects of dichloromethylene diphosphonate in Paget's disease of bone

1 reference

12 December 2020

Routine assay of total urinary hydroxyproline based on resin-catalysed hydrolysis

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.50.12.930

1 reference

28 July 2017

1 reference

28 July 2017

1 reference